Table 2.
Healthcare student participants’ comprehensive responses to survey.
| Survey question | Strongly disagree, n (%) | Disagree, n (%) | Neutral, n (%) | Agree, n (%) | Strongly agree, n (%) |
|---|---|---|---|---|---|
| 1 Pharmacogenomics should be an important part of _____† school curriculum | 4 (0.56) | 23 (3.21) | 183 (25.56) | 391 (54.61) | 115 (16.06) |
| 2 Pharmacogenomics is relevant to current medical practice | 2 (0.28) | 15 (2.09) | 76 (10.61) | 450 (62.85) | 173 (24.16) |
| 3 Pharmacogenomics will be relevant in future medical practice | 1 (0.14) | 3 (0.42) | 29 (4.05) | 341 (47.63) | 342 (47.77) |
| 4 Pharmacogenomics can improve patient care | 1 (0.14) | 2 (0.28) | 74 (10.34) | 416 (58.10) | 223 (31.15) |
| 5 Pharmacogenomics is cost effective | 9 (1.26) | 117 (16.34) | 391 (54.61) | 153 (21.37) | 46 (6.42) |
| 6 Pharmacogenomics can aid in optimizing medication therapy | 0 (0.00) | 3 (0.42) | 74 (10.34) | 400 (55.87) | 239 (33.38) |
| 7 _____‡ should be required to have some comprehension of pharmacogenomics | 2 (0.28) | 14 (1.96) | 99 (13.83) | 456 (63.69) | 145 (20.25) |
| 8 Once in practice, I should be able to answer patient questions on pharmacogenomics | 1 (0.14) | 24 (3.35) | 120 (16.76) | 462 (64.53) | 109 (15.22) |
| 9 Once in practice, I should be able to educate patients on the risks and benefits of pharmacogenomics testing | 1 (0.14) | 23 (3.21) | 118 (16.48) | 461 (64.39) | 113 (15.78) |
| 10 Once in practice, I should be able to identify patients that could benefit from pharmacogenomics testing | 1 (0.14) | 21 (2.93) | 110 (15.36) | 465 (64.94) | 119 (16.62) |
| 11 Once in practice, I should be able to provide drug therapy recommendations based on previously obtained patient genetic information | 5 (0.70) | 53 (7.40) | 134 (18.72) | 403 (56.28) | 121 (16.90) |
| 12 Once in practice, I should be able to identify medications that require pharmacogenomics testing | 2 (0.28) | 20 (2.79) | 114 (15.92) | 428 (59.78) | 152 (21.23) |
| 13 I should have access to my patients pharmacogenetic information in clinical practice | 2 (0.28) | 29 (4.05) | 146 (20.39) | 421 (58.80) | 118 (16.48) |
| 14 I am comfortable interpreting information from a pharmacogenomics test | 193 (26.96) | 314 (43.85) | 130 (18.16) | 68 (9.50) | 11 (1.54) |
| 15 I am comfortable answering questions on pharmacogenomics | 162 (22.63) | 313 (43.72) | 135 (18.85) | 97 (13.55) | 9 (1.26) |
| 16 I am comfortable educating patients on the risks and benefits of pharmacogenomics testing | 173 (24.16) | 314 (43.85) | 124 (17.32) | 97 (13.55) | 8 (1.12) |
| 17 I can apply information from a pharmacogenomics test to medication selection, dosing or monitoring for a patient | 208 (29.05) | 288 (40.22) | 129 (18.02) | 84 (11.73) | 7 (0.98) |
| 18 I know which medications require pharmacogenomics testing | 230 (32.12) | 334 (46.65) | 90 (12.57) | 60 (8.38) | 2 (0.28) |
| 19 Pharmacogenomics has been an important part of my _____† school curriculum | 139 (19.41) | 291 (40.64) | 199 (27.79) | 75 (10.47) | 12 (1.68) |
†
Insert ‘pharmacy’, ‘nursing’ or ‘medical’; particular to specific student population.
‡
Insert ‘pharmacists’, ‘nurses’ or ‘physicians’; particular to specific student population.